About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:3838621
cn7
Allelic
Composition		 Cdkn2atm1Rdp/Cdkn2atm1Rdp
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Pdgfratm12Sor/Pdgfra+
Genetic
Background		 involves: 129 * C57BL/6J * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2atm1Rdp mutation (6 available); any Cdkn2a mutation (66 available)
Gt(ROSA)26Sortm1(cre/ERT)Nat mutation (2 available); any Gt(ROSA)26Sor mutation (1026 available)
Pdgfratm12Sor mutation (1 available); any Pdgfra mutation (87 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
increased sarcoma incidence ( J:146617 )
• all tamoxifen-treated mice develop sarcomas of the skin or muscle connective tissue after 10 to 19 weeks
increased fibrosarcoma incidence ( J:146617 )
• 2 tamoxifen-treated mice develop large intestinal tumors resembling undifferentiated fibrosarcomas

muscle
skeletal muscle interstitial fibrosis ( J:146617 )
• tamoxifen-treated mice develop muscle fibrosis at 10 to 19 weeks of age

integument
skin fibrosis ( J:146617 )
• tamoxifen-treated mice develop skin fibrosis at 10 to 19 weeks of age

digestive/alimentary system
intestinal fibrosis ( J:146617 )
• after 15 weeks, tamoxifen-treated mice exhibit intestinal fibrosis

Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
12/17/2024
MGI 6.24 		The Jackson Laboratory